Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;13(2):449-467.
doi: 10.1007/s40123-023-00870-2. Epub 2024 Jan 5.

Optical Coherence Tomography Angiography: A 2023 Focused Update on Age-Related Macular Degeneration

Beatrice Tombolini  1   2 , Emanuele Crincoli  1   2 , Riccardo Sacconi  1   2 , Marco Battista  1   2 , Federico Fantaguzzi  1   2 , Andrea Servillo  1   2 , Francesco Bandello  1   2 , Giuseppe Querques  3   4
Affiliations
Review

Optical Coherence Tomography Angiography: A 2023 Focused Update on Age-Related Macular Degeneration

Beatrice Tombolini et al. Ophthalmol Ther. 2024 Feb.

Abstract

Optical coherence tomography angiography (OCTA) has extensively enhanced our comprehension of eye microcirculation and of its associated diseases. In this narrative review, we explored the key concepts behind OCTA, as well as the most recent evidence in the pathophysiology of age-related macular degeneration (AMD) made possible by OCTA. These recommendations were updated since the publication in 2020, and are targeted for 2023. Importantly, as a future perspective in OCTA technology, we will discuss how artificial intelligence has been applied to OCTA, with a particular emphasis on its application to AMD study.

Keywords: 3D OCTA; Age-related macular degeneration; Artificial intelligence; Geographic atrophy; Non-exudative macular neovascularization; Optical coherence tomography angiography; Quiescent neovascularization; Subclinical neovascularization; Type 3 macular neovascularization.

PubMed Disclaimer

Conflict of interest statement

Beatrice Tombolini, Emanuele Crincoli, Marco Battista, Federico Fantaguzzi, and Andrea Servillo have nothing to disclose. Riccardo Sacconi has the following disclosures: Abbvie, Bayer, Medivis, Novartis, Roche, and Zeiss. Francesco Bandello has the following disclosures: Allergan, Bayer, Boehringer-Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, Ntc Pharma, Sifi, Thrombogenics, and Zeiss. Giuseppe Querques has the following disclosures: Alimera Sciences, Allergan Inc, Amgen, Heidelberg, KBH, LEH Pharma, Lumithera, Novartis, Bayer Shering-Pharma, Sandoz, Sifi, Soof-Fidia, and Zeiss.

Figures

Fig. 1
Fig. 1
Three-dimensional optical coherence tomography angiography of a 80-years-old male patient affected by type 3 MNV showing two neovessels connecting the deep capillary plexus to the RPE/sub-RPE space. MNV macular neovascularization, RPE retinal pigment epithelium
Fig. 2
Fig. 2
(A–D) Optical coherence tomography angiography of a 75-year-old male patient affected by non-exudative quiescent type 1 macular neovascularization. (A) Baseline OCTA B-scan (left) and en-face (right) at RPE level. Confluent DEPs present detectable flow, representing non-exudative type 1 MNV. (B–D) OCTA B-scan (left) and en-face (right) at RPE level after 6 months (B), 12 months (C), and 18 months (D) did not detect activation signs, thus showing non-exudative quiescent MNV. MNV macular neovascularization, RPE retinal pigment epithelium, DEP pigment epithelium detachments, OCTA optical coherence tomography angiography
Fig. 3
Fig. 3
(A–C) Optical coherence tomography angiography (OCTA) of a 71-year-old female patient affected by type 3 macular neovascularization (T3 MNV) in the fellow eye of a unilateral T3 MNV. A Baseline OCTA B-scan (left) and en-face (right) at deep capillary plexus level. Intraretinal hyperreflective foci (HRF) show detectable flow with no exudation, representing preclinical stage of T3 MNV (nascent T3 MNV), and overlay confluent pigment epithelium detachments (DEPs) with no contact with retinal pigment epithelium (RPE). Yellow panel: B-scan magnification. Blue panel: en-face magnification, with a blue arrow indicating pathological vascular network. (B) 3-month follow-up OCTA B-scan (left) and en-face (right) at RPE level. HRF has grown toward RPE space and connected to DEP, developing exudative signs of overt MNV (blue arrow). (C) 6-month follow-up OCTA B-scan (left) and en-face (right) at retinal pigment epithelium (RPE) level. T3 neovascularization (blue arrow) displays evident signs of activation (intraretinal cysts)
See this image and copyright information in PMC

References

    1. Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1–55. doi: 10.1016/j.preteyeres.2017.11.003. - DOI - PMC - PubMed
    1. Borrelli E, Sarraf D, Freund KB, Sadda SR. OCT angiography and evaluation of the choroid and choroidal vascular disorders. Prog Retin Eye Res. 2018;67:30–55. doi: 10.1016/j.preteyeres.2018.07.002. - DOI - PubMed
    1. Borrelli E, Sadda SVR, Uji A, Querques G. Pearls and pitfalls of optical coherence tomography angiography imaging: a review. Ophthalmol Ther. 2019;8(2):215–226. doi: 10.1007/s40123-019-0178-6. - DOI - PMC - PubMed
    1. Borrelli E, Sadda SR, Uji A, Querques G. OCT angiography: guidelines for analysis and interpretation. In: OCT and Imaging in Central Nervous System Diseases: The Eye as a Window to the Brain: Second Edition. 2020.
    1. Borrelli E, Parravano M, Sacconi R, Costanzo E, Querques L, Vella G, et al. Guidelines on Optical Coherence Tomography Angiography Imaging: 2020 focused update. Ophthalmol Ther. 2020;9(4):697–707. doi: 10.1007/s40123-020-00286-2. - DOI - PMC - PubMed

LinkOut - more resources